Target intelligence / Profile preview

Amyloid fold (Amyloid)

Target
Amyloid
Molecular classification
Protein aggregate, Misfolded protein, Amyloid, Prion-like protein
01

Overview

The amyloid fold is a distinctive protein quaternary structure characterized by a cross-beta sheet motif, where individual beta-strands are oriented perpendicular to the long axis of the fibril. This structural arrangement is the defining feature of amyloidosis, a broad category of diseases where normally soluble proteins misfold and assemble into insoluble, toxic fibers that accumulate in tissues and organs. While many different proteins (such as amyloid-beta, tau, alpha-synuclein, and transthyretin) can form this fold, the resulting fibrils share similar biophysical properties and staining characteristics, such as apple-green birefringence under polarized light when stained with Congo Red. Therapeutic strategies targeting the amyloid fold include monoclonal antibodies designed to recognize and clear aggregated species, small molecules that stabilize the native state of proteins to prevent misfolding, and inhibitors that disrupt the nucleation or growth of the fibrils. The amyloid fold serves as a critical target for both disease-modifying therapies and diagnostic imaging agents in neurodegenerative and systemic diseases.

Other names
Cross-beta structureAmyloid fibrilBeta-amyloid foldAmyloidogenic protein foldMisfolded protein aggregate
02

Mechanism of action

Amyloid clearance via immunotherapy, kinetic stabilization of native protein precursors, inhibition of fibril elongation, and disaggregation of existing fibrils.

03

Biological functions

Protein aggregationPathological proteostasisCellular toxicityFunctional amyloid formation (in specific contexts)
04

Disease associations

Alzheimer's diseaseParkinson's diseaseTransthyretin amyloidosis (ATTR)Systemic AL amyloidosisPrion diseaseType 2 diabetes mellitusHuntington's disease
05

Safety considerations

Amyloid-Related Imaging Abnormalities (ARIA-E and ARIA-H)Infusion-related reactionsOff-target clearance of functional protein isoformsNeuroinflammation
06

Interacting drugs

Aducanumab

8 more in the full profile.

07

Biomarkers

Amyloid PET imaging (e.g., [18F]Florbetapir)Cerebrospinal fluid A-beta 42/40 ratioPlasma Amyloid-beta levelsPhospho-tauSerum amyloid P component (SAP) scintigraphy

Beyond the preview

Go deeper on Amyloid fold (Amyloid).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amyloid fold (Amyloid).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call